A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinsons disease (the ADAGIO study): rationale, design, and baseline characteristics
AMPK-regulated glycerol excretion maintains metabolic crosstalk between reductive and energetic stress
Advantages: Targets autoimmune-driven joint inflammation specifically
BPC-157 Often discussed for recovery, joint comfort, and gut health, and your provider may suggest it as part of a broader recovery plan
Therefore, future research should focus on deepening our understanding of ferroptosis mechanisms in CAD and developing more effective and safer clinical intervention strategies to enhance CHD management
A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder